Market Snapshot

BSE Sensex: 76886.91 -0.54%
BSE 500: 35650.27 -0.28%
BSE 200: 11151.63 -0.32%
BSE 100: 25446.22 -0.38%
BSE BANKEX: 62360.06 -1.61%
BSE IT: 28036.31 -0.78%
Nifty 50: 23995.7 -0.40%
Nifty 500: 22765.6 -0.24%
Nifty 200: 13759.85 -0.26%
Nifty 100: 24955 -0.39%
Nifty Midcap 100: 60419.4 0.28%
Nifty Small 100: 17976.1 0.42%
Nifty IT: 28959.9 -0.68%
Nifty PSU Bank: 8663.05 -2.15%

News:

Artson Q4 PAT spurts 460% YoY ...
Maruti Suzuki slips as Q4 PAT ...
Dalmia Bharat drops after Q4 P...
Blackbuck Ltd leads losers in ...
Linc rallies as board clears c...

Bharat Parenterals Ltd Share Price – BSE
Pharmaceuticals, Small Cap

Invest

28 Apr 2026 | 04:01 PM

1,205.50

-21.80 (-1.78%)

Add to Watchlist

This awesome feature is still in our labs.
Set Alert

This awesome feature is still in our labs.

Outperforms Index

24.41%

Return (1Y)

Beaten BSE Sensex by 28.05%
More Volatile

2.9%

Standard Deviation (1Y)

Higher than BSE Sensex by 2.05%
Not so consistent

5/12

Months

underperformed BSE Sensex
AxisDirect View

No View

52 Week High-Low

1,667

880

News & Announcements

Bharat Parenterals arm Innoxel gets 5 observations after USFDA inspection
7 days ago

Bharat Parenterals arm Innoxel gets 5 observations after USFDA inspection

21 - Apr - 2026 12:00 | 7 days ago

The inspection of the General Injectables Block was carried out from 13 April to 17 April 2026 and concluded on 20 April 2026.
At the conclusion of the inspection, the USFDA issued five observations under a Voluntary Action Indicated (VAI) classification. The company said its subsidiary will respond within the prescribed timeline, while the final Establishment Inspection Report (EIR) is awaited.
The General Injectables Block is a key facility that supports the supply of sterile injectable formulations to regulated markets, including the United States and the European Union.
Commenting on the development, the company?s management said, ?A surprise USFDA inspection of a sterile injectables block, concluding with a few procedural observations under a VAI classification, reflects the consistency of quality and compliance systems at Innoxel. The company continues to focus on strengthening its manufacturing and regulatory capabilities.?
Bharat Parenterals as a pharmaceutical company. The Company develops anti-retroviral drugs in the form of tablets, capsules, oral liquids, eye drops, lotion, creams, and injections for the treatment of various diseases. Bharat Parenterals serves clients in India.
The company reported consolidated net loss of Rs 4.39 crore in Q3 FY26 as against net loss of Rs 1.67 crore in the same quarter last year. Revenue from operations fell 9.8% YoY to Rs 65.19 crore in the quarter ended 31 December 2026.
The counter added 1.31% to Rs 1,201.25 on the BSE.
Bharat Parenterals reports consolidated net loss of Rs 4.39 crore in the December 2025 quarter
87 days ago

Bharat Parenterals reports consolidated net loss of Rs 4.39 crore in the December 2025 quarter

31 - Jan - 2026 12:00 | 87 days ago

Net Loss of Bharat Parenterals reported to Rs 4.39 crore in the quarter ended December 2025 as against net loss of Rs 1.67 crore during the previous quarter ended December 2024. Sales declined 9.78% to Rs 65.19 crore in the quarter ended December 2025 as against Rs 72.26 crore during the previous quarter ended December 2024.

Particulars Quarter Ended
Dec. 2025 Dec. 2024 % Var.

Sales 65.19 72.26 -10

OPM % 2.67 5.04 -

PBDT 0.17 3.25 -95

PBT -8.28 -5.50 -51

NP -4.39 -1.67 -163

Powered by Capital Market - Live News
Bharat Parenterals announces board meeting date
96 days ago

Bharat Parenterals announces board meeting date

22 - Jan - 2026 12:00 | 96 days ago

Bharat Parenterals will hold a meeting of the Board of Directors of the Company on 30 January 2026.
Powered by Capital Market - Live News
Bharat Parenterals reports consolidated net loss of Rs 7.24 crore in the September 2025 quarter
166 days ago

Bharat Parenterals reports consolidated net loss of Rs 7.24 crore in the September 2025 quarter

13 - Nov - 2025 12:00 | 166 days ago

Net Loss of Bharat Parenterals reported to Rs 7.24 crore in the quarter ended September 2025 as against net loss of Rs 7.50 crore during the previous quarter ended September 2024. Sales declined 9.79% to Rs 64.62 crore in the quarter ended September 2025 as against Rs 71.63 crore during the previous quarter ended September 2024.

Particulars Quarter Ended
Sep. 2025 Sep. 2024 % Var.

Sales 64.62 71.63 -10

OPM % 1.28 -10.69 -

PBDT 1.25 -6.36 LP

PBT -7.31 -15.37 52

NP -7.24 -7.50 3

Powered by Capital Market - Live News

Price vs Volume

Stock Trivia

Bharat Parenterals Ltd has opened at 1170.25 i.e -4.65% below then yesterday's closing price of 1227.3

Peer Comparison on Risk - Return

Thanks for Liking, Please spread your love by sharing...

Particulars	Quarter Ended
	Dec. 2025	Dec. 2024	% Var.
Sales	65.19	72.26	-10
OPM %	2.67	5.04	-
PBDT	0.17	3.25	-95
PBT	-8.28	-5.50	-51
NP	-4.39	-1.67	-163

Particulars	Quarter Ended
	Sep. 2025	Sep. 2024	% Var.
Sales	64.62	71.63	-10
OPM %	1.28	-10.69	-
PBDT	1.25	-6.36	LP
PBT	-7.31	-15.37	52
NP	-7.24	-7.50	3

General Notifications

My Notifications

Research Notifications

Bharat Parenterals Ltd Share Price – BSE Pharmaceuticals, Small Cap

1,205.50 -21.80 (-1.78%)

News & Announcements

Price vs Volume

Stock Trivia

Bharat Parenterals Ltd Share Price – BSE
Pharmaceuticals, Small Cap

1,205.50

-21.80 (-1.78%)